Aprea Therapeutics, Inc. (APRE)
NASDAQ: APRE · Real-Time Price · USD
3.010
-0.010 (-0.33%)
Nov 20, 2024, 4:00 PM EST - Market closed
Aprea Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Net Income | -13.51 | -14.29 | -112.66 | -37.13 | -53.48 |
| Depreciation & Amortization | 0.02 | 0.01 | 0.19 | 0.27 | 0.23 |
| Asset Writedown & Restructuring Costs | - | - | 72.52 | - | - |
| Stock-Based Compensation | 0.45 | 0.44 | 16.98 | 7.81 | 4.98 |
| Other Operating Activities | 0.06 | 0.04 | -0.28 | -0.32 | 0.89 |
| Change in Accounts Payable | 0.29 | 0.83 | -0.86 | -2.73 | 2.33 |
| Change in Unearned Revenue | - | 0.53 | - | - | - |
| Change in Other Net Operating Assets | -1.1 | 0.26 | -0.9 | -5.6 | 3.25 |
| Operating Cash Flow | -13.79 | -12.18 | -25.01 | -37.69 | -41.8 |
| Capital Expenditures | -0.02 | -0.09 | - | - | -0.03 |
| Investing Cash Flow | -0.02 | -0.09 | - | - | -0.03 |
| Issuance of Common Stock | 16 | 5.79 | 0.68 | 1.75 | 0.15 |
| Other Financing Activities | -1.31 | -0.65 | - | - | - |
| Financing Cash Flow | 14.69 | 5.14 | 0.68 | 1.75 | 0.15 |
| Foreign Exchange Rate Adjustments | 0.02 | -0.01 | 0.04 | -0 | 0.61 |
| Net Cash Flow | 0.9 | -7.14 | -24.29 | -35.94 | -41.07 |
| Free Cash Flow | -13.81 | -12.27 | -25.01 | -37.69 | -41.83 |
| Free Cash Flow Margin | -1053.38% | -2103.92% | - | - | - |
| Free Cash Flow Per Share | -2.79 | -3.39 | -15.09 | -35.41 | -39.58 |
| Levered Free Cash Flow | -9.26 | -7.67 | -7.97 | - | - |
| Unlevered Free Cash Flow | -9.26 | -7.67 | -7.97 | - | - |
| Change in Net Working Capital | 0.48 | -1.64 | 1.78 | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.